Scholar Rock Heading To Finish Line In SMA With Positive Pivotal Data

Phase III success positions Scholar Rock’s selective myostatin inhibitor for regulatory filings in early 2025. Analysts see a blockbuster opportunity for additive therapy in spinal muscular atrophy.